Novel Brominated and Organophosphate Flame Retardants and Type 2 Diabetes

Save

Report Abuse

Description

As alternative flame retardants (FRs), novel brominated flame retardants (NBFRs) and organophosphate flame retardants (OPFRs) are ubiquitous in environment and may cause endocrine disruption effects. The associations between traditional endocrine-disrupting chemicals (EDCs) and type 2 diabetes have been extensively reported in epidemiological studies. To date, however, human-based evidence on the effects of NBFRs and OPFRs is lacking. The investigators conducted a case-control study of 344 participants aged 25-80 years from Shandong Province, East China, to assess potential associations between serum NBFR and OPFR concentrations and etiology of type 2 diabetes for the first time.

Study Overview

Start Date
January 1, 2022
Completion Date
December 30, 2024
Enrollment
340
Date Posted
February 2, 2024
Gender
All

Locations

Full Address
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong 250000, China

Eligibility

Study Population
we will conduct a case-control study of 340 participants from Shandong 116 Province, East China, to evaluate the associations between serum NBFR and OPFR and risk of type 2 diabetes.
Minimum Age (years)
18
Maximum Age (years)
75
Eligibility Criteria
Inclusion Criteria:

Group of Type 2 diabetes patients:

age 18 ~ 75 years old;
type 2 diabetes patients diagnosed in the First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province) , HBA1C ≥7.0% and <10.5% ;
patients signed informed consent.

Control Group:

age 18 ~ 75 years old;
healthy population recruited from the First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province) ;
living in the monitoring area for more than 6 months within 12 months;
normal thyroid function and no history of thyroid cancer were needed in the control group;
Fasting Blood Glucose level of 0.7 mmol/l was needed in the Control Group of Type 2 diabetes Mellitus Without History of diabetes;
patients with informed consent.

Exclusion Criteria:

Group of Type 2 diabetes:

pregnant, lactating women, patients with acute cardiac cerebrovascular disease;
patients with severe liver and Renal Impairment (related laboratory tests more than 2 times the normal) ;
patients with Type 1 diabetes;
participants in other clinical trials within 3 months;
patients with malignant tumors.
has the disease and so on serious anemia, is not suitable to carry on the patient which the blood draws the test.

Control Group:

patients with serious heart, liver or kidney disease;
patients with iodine or Thyroid hormone;
patients with confirmed malignant tumor;
pregnant women or those who have recently taken contraception or estrogen.

Study Contact Info

Study Contact Name
Guan Xiaoling, Dr.; Jiao Wenjiao, Dr.
Study Contact Email
Study Contact Phone

Contact Listings Owner Form

Novel Brominated and Organophosphate Flame Retardants and Type 2 Diabetes 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
No
FDA Regulated Device?
No
Detailed Description
In this study, the investigators conducted a case-control study in Shandong Province, East China, to evaluate the associations between serum NBFR and OPFR and risk of type 2 diabetes. The aims of the present study were to (1) evaluate the associations between alternative FRs in human serum and the risk of type 2 diabetes, (2) assess the relationships between alternative FR concentrations and fasting plasma glucose (FPG), (3) investigate the correlations between alternative FRs and concentrations of lipid fractions, including TG, TC, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), and (4) clarify the joint effects of NBFR and OPFR mixtures on the risk of type 2 diabetes
NCTid (if applicable)
NCT06239506